Aktienanalyse zu Cibus Inc (CBUS)CBUSCibus Inc

Cibus, Inc. is an agricultural technology company that uses gene-editing technologies to develop plant traits in seeds. Its business is the development of plant traits for some of the agricultural food crops that help address specific productivity, profitability, sustainability, or yield challenges in farming. Its core technology propriety gene editing platform is called the Rapid Trait Development System (RTDS). It is the underlying technology in the Company's Trait Machine process, an end-to-end semi-automated high-throughput gene editing system that directly edits seed companies' elite germplasm. It has a pipeline of five productivity traits. It has developed the productivity trait Pod Shatter Reduction (PSR) in Canola and Winter Oilseed Rape (WOSR) strengthens the sheath around the canola seeds. Its advanced productivity traits, Sclerotinia resistance and HT2 in Canola and WOSR, continue to progress and offer white mold disease resistance and broadleaf weed herbicide tolerance. It operates in the Healthcare sector (AGRICULTURAL CHEMICALS industry).

Cibus Inc is currently not a strong buy due to its low current price of $1.65 and a concerning RSI of 29.375, indicating oversold conditions. While the company has reported a revenue growth of 11% year-over-year in Q2 2026, it also posted a net loss of $22.1 million, which raises concerns about profitability. The analyst price target of $3 suggests potential upside, but the stock's recent performance shows a 14.51% decline over the last 20 days, indicating ongoing weakness. The main risk is the high debt-to-equity ratio of 1718.58%, which could impact financial stability.